Sutykine 50 mg Capsule (Sunitinib) Comprehensive Product Profile: What is Sutykine 50mg? Sutykine 50 mg is a high-potency oral oncology medication containing the active ingredient Sunitinib. Classified as a multikinase inhibitor (TKI), it represents a landmark shift in personalized cancer care. Unlike traditional chemotherapy that non-selectively attacks all rapidly dividing cells, Sutykine is designed to identify and interfere with specific molecular pathways that allow tumors to survive, grow, and spread. Primary Therapeutic Indications Advanced Renal Cell Carcinoma (RCC): Widely recognized as a standard therapy for advanced or metastatic kidney cancer. Gastrointestinal Stromal Tumors (GIST): Utilized for patients with stomach or bowel tumors that have progressed despite previous therapies. Pancreatic Neuroendocrine Tumors (pNET): Treats progressive, well-differentiated tumors located in the pancreas. Adjuvant Treatment: Used to reduce the risk of cancer recurrence following surgery in high-risk kidney cancer patients. Mechanism of Action: How Sutykine Disrupts Cancer Sutykine 50mg operates through a sophisticated “multi-receptor“ blockade to dismantle the tumor's biological infrastructure. Tyrosine Kinase Inhibition: It blocks enzymes known as Tyrosine Kinases located on the surface of cancer cells. These enzymes act as “on-switches“ for growth. By locking these switches in the “off“ position, Sutykine stops the signals that tell cancer cells to multiply. Anti-Angiogenesis Strategy: Sutykine targets Vascular Endothelial Growth Factor (VEGF) and Platelet-Derived Growth Factor (PDGF) receptors. This inhibits the growth of new blood vessels. By cutting off the “nutrient supply lines,“ the tumor is starved of oxygen and essential nutrients. Metastasis Suppression: By disrupting vital survival pathways, the medication helps slow the spread of malignant cells to other parts of the body. Detailed Clinical Instructions To ensure maximum therapeutic efficacy and patient safety, follow these administration guidelines: Dosing Schedule: Sutykine is typically administered in cycles (e.g., 4 weeks of daily treatment followed by a 2-week rest period). Strictly adhere to the specific cycle prescribed by your oncologist. Administration: Swallow the 50mg capsule whole with water. It can be taken with or without food. Integrity: Never crush, chew, or open the capsule, as this can affect the absorption rate and increase the risk of side effects. Consistency: Take your dose at the same time every day to maintain a steady concentration of the drug in your system. Management of Potential Side Effects Sutykine 50 mg is a powerful medication and may cause adverse reactions. Early identification is key: Gastrointestinal: Nausea, diarrhea, vomiting, and “stomatitis“ (mouth sores). Dermatological: Yellowish skin discoloration (non-jaundice), dryness, or Hand-Foot Syndrome (painful redness and swelling on the palms and soles). Cardiovascular: Hypertension (high blood pressure) is common; regular monitoring is essential. Endocrine: Changes in thyroid function (Hypothyroidism) or altered taste (dysgeusia). Hematological: Potential decrease in white blood cell or platelet counts, requiring periodic blood monitoring. Storage and Handling Protocols Environmental Control: Store in a cool, dry place away from direct sunlight and humidity. Temperature Range: Maintain storage at controlled room temperature, ideally between 15°C to 30°C. Child Safety: Keep strictly out of reach of children. Waste Management: Do not dispose of unused capsules in household wastewater. Consult your local pharmacist for proper oncology drug disposal. Why Partner with Ernest Impex? Ernest Impex, under the Ernest Pharmaceutical Pvt. Ltd. group, is a globally recognized pharmaceutical exporter from India, bridging the gap between life-saving Indian generics and global healthcare needs. ✔ GMP Standards: We supply only products that meet rigorous international manufacturing benchmarks. ✔ Global Strategic Logistics: Expert handling of pharmaceutical shipments to the USA, UK, UAE, Australia, and Singapore. ✔ B2B Bulk Specialization: We are a preferred partner for international oncology clinics, hospitals, and wholesale distributors. ✔ Competitive Export Pricing: Access the cost advantages of the Indian pharmaceutical market without compromising on quality. ✔ Comprehensive Documentation: Full support with COA (Certificate of Analysis), invoices, and customs documentation. 📞 Contact Ernest Impex – Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICALS PVT. LTD.] 🌐 Websites www.ernestimpex.com www.ernestpharmaceuticals.com www.oncologuymediciensupplier.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Chat: https://wa.me/919359902383